Deals and M&A

Korea roundup: Alteogen, Celltrion lead biotech deals

Tue, 31 Mar 2026 12:00:00 -0400

Subcutaneous formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.

Korea roundup: Alteogen, Celltrion lead biotech deals

Thu, 26 Mar 2026 12:00:00 -0400

Subcutaneous (SC) formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.

Kyron-Servier deal focused on programmable glycoprotein platform

Mon, 16 Mar 2026 09:00:00 -0400

Newco Kyron Bio is showing its colors after sealing a research agreement with Servier SA, underpinning a claim that it has overcome one of the longest-running challenges of the biotech industry, and developing technology to precisely control the glycosylation of therapeutic proteins.

Kyron-Servier deal focused on programmable glycoprotein platform

Fri, 13 Mar 2026 12:00:00 -0400

Smith+Nephew buying Integrity Orthopaedics for up to $450M

Tue, 13 Jan 2026 11:00:00 -0500

Smith+Nephew plc (S+N) has agreed to acquire Integrity Orthopaedics Inc. for up to $450 million in a bid to strengthen its shoulder repair portfolio. The move comes as the company looks to accelerate its growth with strategic investments, with the deal expected to be an important step in its ambition in becoming a global leader in sports medicine.

Boston Sci’s Valencia buy adds ITNS to urology

Tue, 13 Jan 2026 11:00:00 -0500

Boston Scientific Corp. plans to acquire Valencia Technologies Corp. in the first half of 2026 in a move that will expand its urology portfolio. Valencia makes the Ecoin system, an implantable tibial nerve stimulator (ITNS) designed to treat urge urinary incontinence (UUI). The companies did not disclose terms of the deal, which is not expected to have a material impact on 2026 earnings per share.

Abbott makes cancer screening play with $21B Exact Sciences buy

holland.johnson@clarivate.com — Tue, 14 Oct 2025 00:00:00 -0400

Abbott Laboratories made plans to enter the cancer screening market with its reported acquisition of Exact Sciences Corp. The deal will pay Exact Sciences shareholders $105 per share in cash, a nearly 50% premium to Exact’s unaffected share price on Nov. 19. That represents a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.

Johnson & Johnson plans orthopedics break up

Tue, 14 Oct 2025 00:00:00 -0400

Breaking up isn’t so hard to do, after all. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics unit, which will take with it the Depuy Synthes name first created when Synthes Inc. married into the J&J Depuy ortho unit in 2012 for a tidy sum of $19.7 billion. Depuy was itself acquired in 1998.

Nextcure stock drops near 30% on $745M ADC deal with Simcere

Tue, 17 Jun 2025 11:00:00 -0400

Shares of Nextcure Inc. (NASDAQ:NXTC) dropped 26.27% on news of a potential $745 million partnership with Simcere Zaiming for Simcere’s cadherin-6 antibody-drug conjugate (ADC) candidate. Shares ended at 50 cents apiece June 16.

Analysts are optimistic about outlook for med tech in 2025

Mon, 27 Jan 2025 11:00:00 -0500

With multiple large M&A deals already announced in January, CEOs of major med-tech companies outlining acquisition plans for 2025 and declining interest rates, the stage is set for a significantly more active year of M&A. Financings, too, have ticked up and analysts expect the trend to continue, offering hope for a positive year for the med-tech industry.

Electrocore powers up with Neurometrix acquisition

Wed, 18 Dec 2024 11:00:00 -0500

Electrocore Inc. Quell(ed) any concerns about its commitment to the bioelectronic health segment with an agreement to acquire Neurometrix Inc., maker of the Quell, a wearable device and cloud-enabled neuromodulation platform to treat fibromyalgia and lower extremity chronic pain. Neurometrix is expected to divest its other primary product, Dpncheck, a point-of-care screening test for diabetic peripheral neuropathy, prior to the acquisition.

Jacobio, Allist shake on ¥900M China deal for lung cancer combo

Tue, 03 Sep 2024 14:07:42 -0400

Jacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million (US$126.4 million) deal. Beijing-headquartered Jacobio said Aug. 30 that it signed off development, regulatory and commercial milestone rights to both glecirasib, a KRAS G12C inhibitor first targeting non-small-cell lung cancer, and a SHP2 inhibitor called JAB-3312.

Illumina boldly acquires Fluent Bio weeks after Grail divestiture

Wed, 10 Jul 2024 12:00:00 -0400

Illumina Inc. wasted no time in returning to the M&A front, closing the acquisition of Fluent Biosciences Inc. on July 9 with cash on hand, just a fortnight after freeing itself of Grail Inc. Fluent’s single-cell analysis technology expands Illumina’s presence in the life sciences, possibly marking a turn away from the diagnostics focus that led to the Grail debacle. The acquisition price was not disclosed.

Masimo-Politan mudslinging gets messier

Fri, 05 Jul 2024 12:00:00 -0400

The years’ long effort by activist investor Politan Capital Management LP to take control of the Masimo Corp. board of directors and oust Masimo CEO and founder Joe Kiani took a turn for the weird this week as news emerged that Masimo Chief Operating Officer Bilal Muhsin notified the board that he would step down if Kiani were pushed out.

Quest and Pathai sign multipart collaboration

Thu, 02 May 2024 12:00:00 -0400

Quest Diagnostics Inc. and Pathai Inc. established a forward-looking deal with multiple components and room for growth. The collaboration includes Quest’s acquisition of Pathai Diagnostics – the division that provides anatomic and digital pathology laboratory services – and licensing of Pathai’s Aisight digital pathology image management system. The companies also said they may work together on development of Pathai’s algorithm products and that Quest will be a preferred provider for Pathai’s biopharmaceutical clinical laboratory services.

Eilean Therapeutics acquires PTPN2 inhibitors

Tue, 05 Mar 2024 09:00:00 -0500

Eilean Therapeutics LLC has announced the acquisition of Ness Therapeutics Inc. in an all-equity transaction, including Ness’ best-in-class tyrosine-protein phosphatase non-receptor type 2 (PTPN2) inhibitors with application in immuno-oncology.

Travere licenses out rare kidney disease drug to Renalys in Asia

Tue, 30 Jan 2024 12:00:00 -0500

Travere Therapeutics Inc. inked a licensing deal with Tokyo-based Renalys Pharma Inc. to develop sparsentan in 13 Asian countries, becoming the latest news to heat up the immunoglobulin A nephropathy (IgAN) therapy space.

Travere licenses out rare kidney disease drug to Renalys in Asia

Mon, 29 Jan 2024 12:00:00 -0500

Diasorin unloads cytometry unit at a loss

Tue, 14 Feb 2023 13:00:00 -0500

Diasorin SpA sold its Flow Cytometry and Imaging (FCI) business unit to Cytek Biosciences Inc. for $46.5 million in cash. That’s quite a drop from the $75 million price Diasorin subsidiary Luminex Corp. paid Milleporesigma for the FCI assets in 2018. The companies expect the sale to close within 30 days.

Frizzled sizzles as Surrozen nails down Boehringer deal worth almost $600M

Thu, 06 Oct 2022 12:00:00 -0400

Surrozen Inc.’s back-end-loaded deal with Boehringer Ingelheim GmbH for the preclinical frizzled class receptor 4 agonist SZN-413 takes aim at vascular function in retinal diseases. The arrangement brings an up-front payment to South San Francisco-based Surrozen of $12.5 million, plus up to $586.5 million in potential development, regulatory and commercial milestone rewards, along with mid-single-digit to low-double-digit royalties on sales. After an initial period of joint research, Boehringer, of Ingelheim, Germany, will take over development and commercial responsibilities.

Diagnostic Medical Systems spins out its medical imaging business

Mon, 29 Nov 2021 13:00:00 -0500

PARIS – Diagnostic Medical Systems SA (DMS) is spinning off its medical imaging division into Asit Biotech NV. This agreement, between two firms listed on the Euronext exchange, involves French med-tech company DMS merging its flourishing medical imaging business with the Belgian biopharmaceutical firm and acquiring a controlling stake in the company.

Lumithera envisions brighter future with Diopsys acquisition

Thu, 11 Nov 2021 12:00:00 -0500

Lumithera Inc. will acquire Diopsys Inc. for an undisclosed amount in an all-stock transaction expected to close in the next few months. The deal has been approved by shareholders of both companies. Together, they plan to form a theranostic company that can provide a continuum of care for patients with age-related macular degeneration and other degenerative ocular diseases or injury.

Alivecor taps blockchain technology to connect Kardiamobile users with physicians

Wed, 27 Oct 2021 13:00:00 -0400

Alivecor Inc. is partnering with blockchain technology company Solve.Care to connect users of its Kardiamobile device to physicians through a telehealth network. Tallinn, Estonia-based Solve.Care’s blockchain platform, the Global Telehealth Exchange (GTHE), is an open global cross-border telehealth network currently available in 27 countries. Alivecor’s Kardiamobile 6L device is the first and only six-lead personal ECG cleared by the FDA. Through the partnership, Kardiamobile devices will be integrated with GTHE where physicians will be able to access a user’s electrocardiogram (ECG) reading upon their consent through teleconsultations.

Everly Health seals third acquisition of the year with women’s health startup Natalist

Thu, 21 Oct 2021 13:00:00 -0400

The parent company of digital health unicorn Everlywell Inc. is expanding its portfolio of women’s health products through the acquisition of Charleston, S.C.-based startup Natalist Inc. The purchase marks Everly Health’s third acquisition of the year following agreements to buy national clinician network PWN Health and home lab testing company Home Access Health Corp. Financial terms of all deals were not disclosed. Headquartered in Austin, Texas, Everly Health will add Natalist’s suite of reproductive products to its existing tests for menopause, fertility hormones and sexual health.

Titan takes off with $10M Medtronic license payment

Tue, 15 Jun 2021 13:00:00 -0400

TORONTO – Titan Medical Inc. has received a $10 million license payment from Medtronic plc for a total of $30 million that the Irish med-tech firm has invested in robotic-assisted surgical technologies developed by Titan. Titan is pursuing gynecologic surgical applications for its Enos robotic single access surgical system, licensing it and related intellectual property to Medtronic while retaining worldwide rights to commercialize technologies for use with the Enos system.

Biopharma nonprofit/grant deals triple that of 2019

Wed, 25 Nov 2020 12:00:00 -0500

The combined total of biopharma nonprofit collaborations and grants in 2020 has reached about $24 billion, more than three times the amount recorded for 2019.

Daily M&A

Mon, 30 Sep 2019 00:00:00 -0400

Daily M&A

Fri, 27 Sep 2019 00:00:00 -0400

Daily M&A

Wed, 25 Sep 2019 00:00:00 -0400

Daily M&A

Tue, 24 Sep 2019 00:00:00 -0400